Need Assistance?

US & Canada:
+
UK: +

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

N,N'-Di-Boc-1H-pyrazole-1-carboxamidine

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

N,N'-Bis-Boc-1-Guanylpyrazole is used in the stereoselective synthesis of the bicyclic guanidine alkaloid (+)-monanchorin.

Category

Peptide Synthesis Reagents

Catalog number

BAT-006291

CAS number

152120-54-2

Molecular Formula

C14H22N4O4

Molecular Weight

310.35

Specification
Reference Reading

IUPAC Name

tert-butyl (NZ)-N-[[(2-methylpropan-2-yl)oxycarbonylamino]-pyrazol-1-ylmethylidene]carbamate

Synonyms

[[[(1,1-Dimethylethoxy)carbonyl]amino]-1H-pyrazol-1-ylmethylene]-carbamic Acid 1,1-Dimethylethyl Ester; 1-[N,N'-Di(tert-butoxycarbonyl)amidino]-1H-pyrazole; 1H-Pyrazole-1-N,N'-bis(tert-butoxycarbonyl)carboxamidine; N,N'-Bis(tert-butoxycarbonyl)-1-guanylpyrazole; N,N'-Bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine; N,N'-Bis-Boc-1-guanylpyrazole; N,N'-Di(tert-butyl)oxycarbonyl-1H-pyrazole-1-carboximidamide; N,N'-Di-Boc-1H-pyrazole-1-carboxamidine; N,N'-Di-boc-1H-pyrazole-1-carboximidamide; [[(tert-Butoxycarbonyl)imino](pyrazol-1-yl)methyl]carbamic Acid tert-Butyl Ester; tert-Butyl [(Boc-amino)(1H-pyrazol-1-yl)methylene]carbamate; tert-Butyl,((tert-butoxycarbonyl)amino)(1H-pyrazol-1-yl)methylene)carbamate; 1-[N,N'-(Di-Boc)carbamimidoyl]pyrazole; 1-[N,N'-(Di-Boc)amidino]pyrazole; Pyrazol(Boc)2

Appearance

White powder

Purity

98 % (HPLC)

Density

1.160±0.10 g/cm³ (Predicted)

Melting Point

86-90 °C

Storage

2-8 °C under inert atmosphere

Solubility

Slightly soluble in Water, Methanol, Chloroform

InChI

InChI=1S/C14H22N4O4/c1-13(2,3)21-11(19)16-10(18-9-7-8-15-18)17-12(20)22-14(4,5)6/h7-9H,1-6H3,(H,16,17,19,20)

InChI Key

QFNFDHNZVTWZED-UHFFFAOYSA-N

Canonical SMILES

CC(C)(C)OC(=O)NC(=NC(=O)OC(C)(C)C)N1C=CC=N1

1. Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA

Bo Ye, et al. RNA Biol. 2020 Nov;17(11):1666-1673. doi: 10.1080/15476286.2019.1679585. Epub 2019 Oct 18.

Non-coding RNAs occupy a significant fraction of the human genome. Their biological significance is backed up by a plethora of emerging evidence. One of the most robust approaches to demonstrate non-coding RNA's biological relevance is through their prognostic value. Using the rich gene expression data from The Cancer Genome Altas (TCGA), we designed Advanced Expression Survival Analysis (AESA), a web tool which provides several novel survival analysis approaches not offered by previous tools. In addition to the common single-gene approach, AESA computes the gene expression composite score of a set of genes for survival analysis and utilizes permutation test or cross-validation to assess the significance of log-rank statistic and the degree of over-fitting. AESA offers survival feature selection with post-selection inference and utilizes expanded TCGA clinical data including overall, disease-specific, disease-free, and progression-free survival information. Users can analyse either protein-coding or non-coding regions of the transcriptome. We demonstrated the effectiveness of AESA using several empirical examples. Our analyses showed that non-coding RNAs perform as well as messenger RNAs in predicting survival of cancer patients. These results reinforce the potential prognostic value of non-coding RNAs. AESA is developed as a module in the freely accessible analysis suite MutEx.